AU2001293233A1 - Aza heterocyclic derivatives and their therapeutic use - Google Patents

Aza heterocyclic derivatives and their therapeutic use

Info

Publication number
AU2001293233A1
AU2001293233A1 AU2001293233A AU9323301A AU2001293233A1 AU 2001293233 A1 AU2001293233 A1 AU 2001293233A1 AU 2001293233 A AU2001293233 A AU 2001293233A AU 9323301 A AU9323301 A AU 9323301A AU 2001293233 A1 AU2001293233 A1 AU 2001293233A1
Authority
AU
Australia
Prior art keywords
sup
therapeutic use
heterocyclic derivatives
pharmaceutically acceptable
aza heterocyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001293233A
Inventor
Tim Machajewski
Sabina Pecci
Paul Renhowe
Cynthia Shafer
Mary-Ellen Wernette-Hammond
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of AU2001293233A1 publication Critical patent/AU2001293233A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Abstract

Organic compounds having the structural formula I are provided where the variables have the values described herein and R<SUP>1 </SUP>and R<SUP>2 </SUP>join together to form a 6 membered substituted or unsubstituted ring including at least one O, N, or S atom, and Z is an O, S, NH or NR group. Pharmaceutical formulations include the organic compound or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
AU2001293233A 2000-09-01 2001-08-30 Aza heterocyclic derivatives and their therapeutic use Abandoned AU2001293233A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23182900P 2000-09-01 2000-09-01
US60/231,829 2000-09-01
PCT/US2001/041942 WO2002018383A2 (en) 2000-09-01 2001-08-30 Aza heterocyclic derivatives and their therapeutic use

Publications (1)

Publication Number Publication Date
AU2001293233A1 true AU2001293233A1 (en) 2002-03-13

Family

ID=22870779

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001293233A Abandoned AU2001293233A1 (en) 2000-09-01 2001-08-30 Aza heterocyclic derivatives and their therapeutic use

Country Status (9)

Country Link
US (4) US6756383B2 (en)
EP (1) EP1313734B1 (en)
JP (2) JP4341949B2 (en)
AT (1) ATE448226T1 (en)
AU (1) AU2001293233A1 (en)
DE (1) DE60140456D1 (en)
ES (1) ES2334641T3 (en)
PT (1) PT1313734E (en)
WO (1) WO2002018383A2 (en)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60140456D1 (en) 2000-09-01 2009-12-24 Novartis Vaccines & Diagnostic AZA HETEROCYCLIC DERIVATIVES AND ITS THERAPEUTIC USE
US20030028018A1 (en) * 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
EP1849782A1 (en) 2000-09-11 2007-10-31 Novartis Vaccines and Diagnostics, Inc. Quinolinone derivatives as tyrosine kinase inhibitors
US7642278B2 (en) * 2001-07-03 2010-01-05 Novartis Vaccines And Diagnostics, Inc. Indazole benzimidazole compounds
JP2004536113A (en) * 2001-07-03 2004-12-02 カイロン コーポレイション Indazole benzimidazole compounds as inhibitors of tyrosine kinase and serine / threonine kinase
US20050256157A1 (en) * 2002-08-23 2005-11-17 Chiron Corporation Combination therapy with CHK1 inhibitors
CA2496164C (en) * 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
EP1545529A4 (en) * 2002-09-30 2010-03-03 Bristol Myers Squibb Co Novel tyrosine kinase inhibitors
BR0316229A (en) * 2002-11-13 2005-10-04 Chiron Corp Cancer Treatment Methods and Related Methods
EP1581539A4 (en) * 2003-01-03 2007-09-19 Bristol Myers Squibb Co Novel tyrosine kinase inhibitors
WO2004069160A2 (en) * 2003-01-28 2004-08-19 Smithkline Beecham Corporation Chemical compounds
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
EP2762475A1 (en) * 2003-11-07 2014-08-06 Novartis Vaccines and Diagnostics, Inc. Pharmaceutically acceptable salts of quinolinone compounds and their medical use
FR2862969A1 (en) * 2003-11-28 2005-06-03 Oreal PROCESS FOR THE PREPARATION OF NITROGEN-SUBSTITUTED PYRROLIDINYL GROUP PARAPHENYLENEDIAMINE DERIVATIVES AND INTERMEDIATE COMPOUNDS
CN1960731B (en) * 2004-02-20 2011-12-07 诺华疫苗和诊断公司 Method for regulating inflammatory and metastatic processes
US20060183750A1 (en) 2005-01-27 2006-08-17 Chiron Corporation Treatment of metastasized tumors
NZ597685A (en) 2005-02-18 2013-12-20 Novartis Vaccines & Diagnostic Proteins and nucleic acids from meningitis/sepsis-associated escherichia coli
EP1858919B1 (en) 2005-02-18 2012-04-04 Novartis Vaccines and Diagnostics, Inc. Immunogens from uropathogenic escherichia coli
DK1885187T3 (en) 2005-05-13 2013-12-09 Novartis Ag Method of Treating Drug-Resistant Cancer
AU2006247062A1 (en) 2005-05-17 2006-11-23 Novartis Ag Methods for synthesizing heterocyclic compounds
CA2609353C (en) * 2005-05-23 2015-04-28 Novartis Ag Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
CA2615626A1 (en) 2005-07-18 2007-01-25 Novartis Ag Small animal model for hcv replication
US7915286B2 (en) 2005-09-16 2011-03-29 Ranbaxy Laboratories Limited Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors
JP2009514839A (en) 2005-11-04 2009-04-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル Adjuvant influenza vaccine containing cytokine inducer
AU2006310163B2 (en) 2005-11-04 2011-09-15 Seqirus UK Limited Influenza vaccine with reduced amount of oil-in-water emulsion as adjuvant
CN102727885A (en) 2005-11-04 2012-10-17 诺华疫苗和诊断有限公司 Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
CA2628152C (en) 2005-11-04 2016-02-02 Novartis Vaccines And Diagnostics S.R.L. Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture
MY148529A (en) 2005-11-29 2013-04-30 Novartis Ag Formulations of quinolinones
WO2007067968A2 (en) 2005-12-08 2007-06-14 Novartis Ag Effects of inhibitors of fgfr3 on gene transcription
CA2640248A1 (en) 2006-01-27 2007-08-02 Novartis Vaccines And Diagnostics Gmbh & Co Kg. Influenza vaccines containing hemagglutinin and matrix proteins
ES2376492T3 (en) 2006-03-23 2012-03-14 Novartis Ag IMIDAZOQUINOXALINE COMPOUNDS AS IMMUNOMODULATORS.
CA2646349A1 (en) 2006-03-24 2007-10-04 Novartis Vaccines And Diagnostics Gmbh & Co Kg Storage of influenza vaccines without refrigeration
US20100285062A1 (en) 2006-03-31 2010-11-11 Novartis Ag Combined mucosal and parenteral immunization against hiv
PL2054431T3 (en) 2006-06-09 2012-07-31 Novartis Ag Conformers of bacterial adhesins
GB0614460D0 (en) 2006-07-20 2006-08-30 Novartis Ag Vaccines
GB0614471D0 (en) 2006-07-20 2006-08-30 Syngenta Ltd Herbicidal Compounds
WO2008020330A2 (en) 2006-08-16 2008-02-21 Novartis Ag Immunogens from uropathogenic escherichia coli
EP3456348A1 (en) 2006-09-11 2019-03-20 Seqirus UK Limited Making influenza virus vaccines without using eggs
PT2121011E (en) 2006-12-06 2014-07-31 Novartis Ag Vaccines including antigen from four strains of influenza virus
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
CA2692200A1 (en) 2007-06-27 2008-12-31 Novartis Ag Low-additive influenza vaccines
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
GB0810305D0 (en) 2008-06-05 2008-07-09 Novartis Ag Influenza vaccination
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
GB0800855D0 (en) * 2008-01-17 2008-02-27 Syngenta Ltd Herbicidal compounds
EP2889042A3 (en) 2008-03-18 2015-10-14 Novartis AG Improvements in preparation of influenza virus vaccine antigens
JP2012519482A (en) 2009-03-06 2012-08-30 ノバルティス アーゲー Chlamydia antigen
SI2510947T1 (en) 2009-04-14 2016-05-31 Glaxosmithkline Biologicals S.A. Compositions for immunising against Staphylococcus aureus
BE1019643A3 (en) 2009-04-27 2012-09-04 Novartis Ag INFLUENZA PROTECTION VACCINES.
SG177533A1 (en) 2009-07-07 2012-02-28 Novartis Ag Conserved escherichia coli immunogens
HRP20220756T1 (en) 2009-07-15 2022-09-02 Glaxosmithkline Biologicals S.A. Rsv f protein compositions and methods for making same
CN102770443A (en) 2009-07-16 2012-11-07 诺华有限公司 Detoxified escherichia coli immunogens
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
WO2011051212A1 (en) * 2009-10-28 2011-05-05 Basf Se Use of heteroaromatic compounds as herbicides
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
JP5781542B2 (en) 2009-12-30 2015-09-24 ノバルティス アーゲー E. polysaccharide immunogen conjugated to an E. coli carrier protein
CN102933267B (en) 2010-05-28 2015-05-27 泰特里斯在线公司 Interactive hybrid asynchronous computer game infrastructure
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
EP4144368A1 (en) 2011-01-26 2023-03-08 GlaxoSmithKline Biologicals S.A. Rsv immunization regimen
US20140248314A1 (en) 2011-05-13 2014-09-04 Novartis Ag Pre-fusion rsv f antigens
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
JP6088507B2 (en) 2011-07-08 2017-03-01 ノバルティス アーゲー Tyrosine ligation method
JP6170932B2 (en) 2011-11-07 2017-07-26 ノバルティス アーゲー Carrier molecule comprising spr0096 antigen and spr2021 antigen
WO2013108272A2 (en) 2012-01-20 2013-07-25 International Centre For Genetic Engineering And Biotechnology Blood stage malaria vaccine
KR20150060986A (en) 2012-10-02 2015-06-03 글락소스미스클라인 바이오로지칼즈 에스.에이. Nonlinear saccharide conjugate
EP2870974A1 (en) 2013-11-08 2015-05-13 Novartis AG Salmonella conjugate vaccines
EP2977374A1 (en) 2014-07-21 2016-01-27 Université de Strasbourg Molecules presenting dual emission properties
CA2989684A1 (en) * 2015-06-25 2016-12-29 University Health Network Hpk1 inhibitors and methods of using same
CN107935858B (en) * 2016-10-12 2020-09-08 利尔化学股份有限公司 Preparation method of 5-fluoro-2-nitrophenol
KR20200092987A (en) * 2017-11-24 2020-08-04 얀센 파마슈티카 엔.브이. Pyrazolopyridinone compounds
WO2019101183A1 (en) * 2017-11-24 2019-05-31 Janssen Pharmaceutica Nv Pyrazolopyridinone compounds

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE290153C (en)
DE2363459A1 (en) 1973-12-20 1975-06-26 Basf Ag 7-Amino-quinoline cpds. - for use as optical brighteners, dyes, colour formers in copying and in printing pastes
DE3634066A1 (en) 1986-10-07 1988-04-21 Boehringer Mannheim Gmbh NEW 5-ALKYLBENZIMIDAZOLES, PROCESS FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS
US5073492A (en) 1987-01-09 1991-12-17 The Johns Hopkins University Synergistic composition for endothelial cell growth
DE3739366A1 (en) 1987-04-10 1988-10-27 Boehringer Mannheim Gmbh DESAZA-PURIN-NUCLEOSIDE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN NUCLEIC ACID SEQUENCING AND AS AN ANTIVIRAL AGENT
JPH0699497B2 (en) 1987-04-16 1994-12-07 富士写真フイルム株式会社 Photopolymerizable composition
GB8709448D0 (en) 1987-04-21 1987-05-28 Pfizer Ltd Heterobicyclic quinoline derivatives
DE3932953A1 (en) 1989-10-03 1991-04-11 Boehringer Mannheim Gmbh NEW 2-BICYCLO-BENZIMIDAZOLES, METHOD FOR THEIR PRODUCTION AND MEDICINAL PRODUCTS CONTAINING THESE COMPOUNDS
GB9107742D0 (en) 1991-04-11 1991-05-29 Rhone Poulenc Agriculture New compositions of matter
GB9108369D0 (en) 1991-04-18 1991-06-05 Rhone Poulenc Agriculture Compositions of matter
GB9108547D0 (en) 1991-04-22 1991-06-05 Fujisawa Pharmaceutical Co Quinoline derivatives
DE69222637T2 (en) * 1991-05-10 1998-02-26 Rhone Poulenc Rorer Int UP TO MONO AND BICYCLIC ARYL AND HETEROARYL DERIVATIVES WITH INHIBITING EFFECT ON EGF AND / OR PDGF RECEPTOR TYROSINKINASE
US5480883A (en) 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
USRE37650E1 (en) 1991-05-10 2002-04-09 Aventis Pharmacetical Products, Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5856115A (en) 1991-05-24 1999-01-05 Fred Hutchinson Cancer Research Center Assay for identification therapeutic agents
DE4129603A1 (en) * 1991-09-06 1993-03-11 Thomae Gmbh Dr K CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS
AU3737893A (en) 1992-03-05 1993-10-05 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
JP3142378B2 (en) 1992-06-22 2001-03-07 ティーディーケイ株式会社 Organic EL device
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
US5981569A (en) 1992-11-13 1999-11-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Substituted phenylacrylonitrile compounds and compositions thereof for the treatment of disease
US5763441A (en) 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
JPH0743896A (en) 1993-07-28 1995-02-14 Toyobo Co Ltd Photopolymerizable composition
AU5881394A (en) 1994-01-08 1995-08-01 Rhone-Poulenc Agriculture Limited Benzimidazolyl quinoline-3-carboxylate derivatives, intermediates thereto, and their use as herbicides
JPH0829973A (en) 1994-07-11 1996-02-02 Toyobo Co Ltd Photopolymerized composition
JP3441246B2 (en) 1995-06-07 2003-08-25 富士写真フイルム株式会社 Photopolymerizable composition
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
WO1997034876A1 (en) 1996-03-15 1997-09-25 Zeneca Limited Cinnoline derivatives and use as medicine
DE19610723A1 (en) 1996-03-19 1997-09-25 Bayer Ag Electroluminescent devices using glare systems
US5942385A (en) 1996-03-21 1999-08-24 Sugen, Inc. Method for molecular diagnosis of tumor angiogenesis and metastasis
WO1997048697A1 (en) 1996-06-19 1997-12-24 Rhone-Poulenc Rorer Limited Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
AU727708B2 (en) 1996-06-20 2000-12-21 Board Of Regents, The University Of Texas System Compounds and methods for providing pharmacologically active preparations and uses thereof
WO1998013350A1 (en) 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
AU8816298A (en) 1997-08-22 1999-03-16 Zeneca Limited Oxindolylquinazoline derivatives as angiogenesis inhibitors
DE19756235A1 (en) 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab New piperidinyl-substituted pyridylalkane alkene and alkane carboxylic acid amides
CA2312953A1 (en) * 1998-03-31 1999-10-07 Warner-Lambert Company Quinolones as serine protease inhibitors
WO1999059636A1 (en) 1998-05-20 1999-11-25 Kyowa Hakko Kogyo Co., Ltd. Vegf activity inhibitors
ATE274510T1 (en) 1998-06-19 2004-09-15 Chiron Corp GLYCOGEN SYNTHASE KINASE 3 INHIBITORS
EP1091945A1 (en) 1998-06-29 2001-04-18 Du Pont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
FR2781218B1 (en) 1998-07-15 2001-09-07 Lafon Labor PHARMACEUTICAL COMPOSITIONS COMPRISING 2-QUINOLONES
EP1109555A4 (en) * 1998-08-31 2001-11-21 Merck & Co Inc Novel angiogenesis inhibitors
DE19841985A1 (en) 1998-09-03 2000-03-09 Schering Ag New heterocyclic alkanesulfonic and alkane carboxylic acid derivatives are VEGF receptor blockers useful in treatment of e.g. psoriasis, rheumatoid arthritis, stroke, tumors and endometriosis
AU1099000A (en) 1998-10-05 2000-04-26 Axys Pharmaceuticals, Inc. Novel compounds and compositions for treating hepatitis c infections
IL126953A0 (en) 1998-11-08 1999-09-22 Yeda Res & Dev Pharmaceutical compositions comprising porphyrins and some novel porphyrin derivatives
KR100373203B1 (en) 1999-03-31 2003-02-25 주식회사 엘지화학 New organometallic complexes for use in light emitting devices
CN1351498B (en) 1999-05-21 2012-08-15 布里斯托尔-迈尔斯斯奎布公司 Pyrrolotriazines inhibitors of kinases
PE20010306A1 (en) 1999-07-02 2001-03-29 Agouron Pharma INDAZOLE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM USEFUL FOR THE INHIBITION OF PROTEIN KINASE
KR100681724B1 (en) * 1999-10-19 2007-02-28 머크 앤드 캄파니 인코포레이티드 Tyrosine kinase inhibitors and pharmaceutical compositions comprising the same
CA2387840A1 (en) * 1999-10-19 2001-04-26 Scott R. Hambaugh Tyrosine kinase inhibitors
JP2003520254A (en) 2000-01-19 2003-07-02 エス． ジル，パーカッシュ Methods and compositions relating to antisense VEGF oligonucleotides
GB0001930D0 (en) 2000-01-27 2000-03-22 Novartis Ag Organic compounds
WO2001062252A1 (en) 2000-02-25 2001-08-30 Merck & Co., Inc. Tyrosine kinase inhibitors
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
US6313138B1 (en) 2000-02-25 2001-11-06 Merck & Co., Inc. Tyrosine kinase inhibitors
DE60140456D1 (en) 2000-09-01 2009-12-24 Novartis Vaccines & Diagnostic AZA HETEROCYCLIC DERIVATIVES AND ITS THERAPEUTIC USE
EP1849782A1 (en) 2000-09-11 2007-10-31 Novartis Vaccines and Diagnostics, Inc. Quinolinone derivatives as tyrosine kinase inhibitors
US20030028018A1 (en) 2000-09-11 2003-02-06 Chiron Coporation Quinolinone derivatives
WO2002032861A2 (en) 2000-10-17 2002-04-25 Merck & Co., Inc. Orally active salts with tyrosine kinase activity
JP2004536113A (en) 2001-07-03 2004-12-02 カイロン コーポレイション Indazole benzimidazole compounds as inhibitors of tyrosine kinase and serine / threonine kinase
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
EP1545529A4 (en) 2002-09-30 2010-03-03 Bristol Myers Squibb Co Novel tyrosine kinase inhibitors
BR0316229A (en) 2002-11-13 2005-10-04 Chiron Corp Cancer Treatment Methods and Related Methods
EP1608369B1 (en) 2003-03-28 2013-06-26 Novartis Vaccines and Diagnostics, Inc. Use of organic compounds for immunopotentiation
US6774327B1 (en) 2003-09-24 2004-08-10 Agilent Technologies, Inc. Hermetic seals for electronic components
EP2762475A1 (en) 2003-11-07 2014-08-06 Novartis Vaccines and Diagnostics, Inc. Pharmaceutically acceptable salts of quinolinone compounds and their medical use
WO2005053692A1 (en) 2003-12-01 2005-06-16 The Scripps Research Institute Advanced quinolinone based protein kinase inhibitors
US20060183750A1 (en) 2005-01-27 2006-08-17 Chiron Corporation Treatment of metastasized tumors

Also Published As

Publication number Publication date
WO2002018383A2 (en) 2002-03-07
US20050137188A1 (en) 2005-06-23
US6759417B2 (en) 2004-07-06
US20070032528A1 (en) 2007-02-08
JP2004507543A (en) 2004-03-11
DE60140456D1 (en) 2009-12-24
JP2007217427A (en) 2007-08-30
EP1313734B1 (en) 2009-11-11
US20040002518A1 (en) 2004-01-01
EP1313734A2 (en) 2003-05-28
PT1313734E (en) 2010-02-09
US7138409B2 (en) 2006-11-21
JP4341949B2 (en) 2009-10-14
US7368459B2 (en) 2008-05-06
US20020103230A1 (en) 2002-08-01
ATE448226T1 (en) 2009-11-15
WO2002018383A3 (en) 2002-08-29
ES2334641T3 (en) 2010-03-15
US6756383B2 (en) 2004-06-29

Similar Documents

Publication Publication Date Title
AU2001293233A1 (en) Aza heterocyclic derivatives and their therapeutic use
TR200200579T2 (en) Amino-thyrazolpyridine derivatives.
YU69902A (en) New piperazine derivatives
BG103945A (en) Derivatives of 4&#34;-substituted-9-deoxo-9a-aza-9a-homoerythromycin a
WO2003013484A3 (en) N-monoacylated derivatives of o-phenylenediamines, their six membered heterocyclic analogues and their use as pharmaceutical agents
DE69528005T2 (en) Prolineamid derivatives
DE69933573D1 (en) CHINAZOLINE DERIVATIVES AS MEDICAMENTS
ES2147836T3 (en) DERIVATIVES OF 4,5-DIARILOXAZOLE.
AP9801378A0 (en) 9-amino-3- keto erythromycin derivatives.
EP0386675A3 (en) Xanthine derivatives
KR960701878A (en) Water-soluble camptothecin derivatives, process for their preparation and their use as antitumor agents
AU1247195A (en) Cyclic amide derivatives as neurokinin a antagonists
CA2386813A1 (en) Bicyclic imidazo-3-yl amine derivatives substituted on the 6-membered ring
YU30603A (en) Bridged piperazine derivatives
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
FI101227B1 (en) Process for the preparation of pharmaceutically active 4-deoxy-4-epipodophyllotoxin derivatives
AP9801377A0 (en) Tricyclic erythromycin derivatives.
MXPA02004441A (en) Isoxazole derivatives to be used as phosphodiesterase vii inhibitors.
DE69330601D1 (en) SEROTON INERGIC ERGOLIN DERIVATIVES
WO2001017955A3 (en) Hydroxyacetamidobenzenesulphonamide derivatives
DE69828390D1 (en) DIAMINOTRIFLUOROMETHYLPYRIMIDIN DERIVATIVES ANTICREASIC COMPOSITION
AP2002002595A0 (en) Heterocyclic amide derivatives.
EP2266566A3 (en) Nicotinamide derivatives and their use as therapeutic agents
DE60021109D1 (en) AMYCOMYCIN, METHOD FOR ITS PREPARATION AND ITS USE AS A MEDICAMENT
TH50555A (en) Imidazopyridin derivatives as an inhibitor of phosphodysterase VII.